Raymond James Reinstates Market Perform on Sage Therapeutics
Portfolio Pulse from Benzinga Newsdesk
Raymond James analyst Danielle Brill has reinstated a Market Perform rating on Sage Therapeutics (NASDAQ:SAGE).

October 10, 2024 | 12:59 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Raymond James has reinstated a Market Perform rating on Sage Therapeutics, indicating a neutral stance on the stock.
The reinstatement of a Market Perform rating by Raymond James suggests a neutral outlook on Sage Therapeutics. This indicates that the stock is expected to perform in line with the market, which may not lead to significant short-term price movements.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100